Skip to main content

Spruce Street Capital LP

13F filer · CIK 0002050194
Reported Aug 13, 2026
Net buyer this quarter
13F portfolio value$510MU.S. long equity reported on 13F
Positions305 new · 3 closed
Net flow last quarter+$17.3MBuys minus sells
Top 10 positions weight70.2%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 13, 202630 positions
KNSAKiniksa Pharmaceuticals International, plc$58.7M11.52%Not reported+20.6%Q4 2025
RLAYRelay Therapeutics, Inc.$55.8M10.95%1.37%Not reportedQ4 2025
LBRXLB Pharmaceuticals Inc$44.7M8.76%4.80%Not reportedQ4 2025
RLMDRelmada Therapeutics, Inc.$44.2M8.68%5.99%+2.1%Q4 2025
ANROAlto Neuroscience, Inc.$35.7M7.01%3.86%+2.1%Q4 2025
DNTHDianthus Therapeutics, Inc.$34.6M6.79%0.65%-4.9%Q4 2025
ALKSAlkermes plc.$28.5M5.59%0.32%+71.0%Q1 2026
SVRASavara Inc$21.3M4.17%1.68%+2.1%Q4 2025
PCVXVaxcyte, Inc.$17.8M3.49%0.21%+24.6%Q4 2025
ELVNEnliven Therapeutics, Inc.$16.7M3.28%0.45%Not reportedQ4 2025
ENTAEnanta Pharmaceuticals Inc$15.9M3.11%3.74%+16.7%Q4 2025
CATXPerspective Therapeutics, Inc.$12.6M2.47%3.24%+40.6%Q1 2026
IFRXInflaRx N.V.$12M2.35%7.40%NewQ2 2026
SRZNSurrozen, Inc.$11.2M2.20%3.68%Not reportedQ4 2025
ALMSAlumis Inc.$11M2.17%Not reportedNot reportedQ1 2026
IPSCCentury Therapeutics, Inc.$9.94M1.95%2.25%Not reportedQ4 2025
NERVMinerva Neurosciences, Inc.$9.19M1.80%3.51%Not reportedQ4 2025
SABSSAB Biotherapeutics, Inc.$8.57M1.68%2.63%Not reportedQ4 2025
ANTXAN2 Therapeutics, Inc.$8.04M1.58%4.57%Not reportedQ1 2026
ERASErasca, Inc.$7.74M1.52%0.14%Not reportedQ4 2025
IKTInhibikase Therapeutics, Inc.$7.27M1.43%2.71%Not reportedQ4 2025
RACCResearch Alliance Corp III$5.35M1.05%Not reportedNewQ2 2026
HLXCHelix Acquisition Corp. III$5.32M1.04%Not reportedNot reportedQ1 2026
ZLABZai Lab Ltd$5.3M1.04%0.02%NewQ2 2026
ACHVAchieve Life Sciences, Inc.$4.81M0.94%0.72%NewQ2 2026
LXEOLexeo Therapeutics, Inc.$4.32M0.85%1.18%Not reportedQ4 2025
ALECAlector, Inc.$4.22M0.83%1.88%Not reportedQ4 2025
LONALeonaBio, Inc.$3.62M0.71%4.18%Not reportedQ4 2025
CRVSCorvus Pharmaceuticals, Inc.$3.46M0.68%0.28%Not reportedQ1 2026
JATTJATT II Acquisition Corp.$1.82M0.36%8.89%NewQ2 2026
Q1 2026Reported May 14, 202628 positions
RLMDRelmada Therapeutics, Inc.$43M10.34%5.97%+53.3%Q4 2025
KNSAKiniksa Pharmaceuticals International, plc$36.6M8.81%Not reported+75.0%Q4 2025
LBRXLB Pharmaceuticals Inc$33.6M8.09%4.80%+36.9%Q4 2025
DNTHDianthus Therapeutics, Inc.$31.3M7.53%0.68%+25.5%Q4 2025
RLAYRelay Therapeutics, Inc.$29.7M7.14%1.58%Not reportedQ4 2025
ANROAlto Neuroscience, Inc.$29.1M7.00%3.78%+494.7%Q4 2025
CNTACentessa Pharmaceuticals PLC$19.5M4.68%0.32%+528.0%Q4 2025
SVRASavara Inc$18.5M4.44%1.65%+40.3%Q4 2025
KALVKalVista Pharmaceuticals, Inc.$18.1M4.34%1.75%+131.4%Q4 2025
PCVXVaxcyte, Inc.$14.3M3.43%0.17%-38.6%Q4 2025
ELVNEnliven Therapeutics, Inc.$12.9M3.10%0.54%-26.3%Q4 2025
SRZNSurrozen, Inc.$12.6M3.03%3.76%Not reportedQ4 2025
ENTAEnanta Pharmaceuticals Inc$11.8M2.83%3.21%+139.3%Q4 2025
ALKSAlkermes plc.$11.2M2.70%0.19%NewQ1 2026
CATXPerspective Therapeutics, Inc.$11M2.63%2.30%NewQ1 2026
NERVMinerva Neurosciences, Inc.$9.97M2.40%3.78%Not reportedQ4 2025
IPSCCentury Therapeutics, Inc.$9.17M2.21%2.25%+185.5%Q4 2025
ALMSAlumis Inc.$8.65M2.08%Not reportedNewQ1 2026
SABSSAB Biotherapeutics, Inc.$8.42M2.02%2.90%Not reportedQ4 2025
ERASErasca, Inc.$6.84M1.64%0.14%-89.1%Q4 2025
IKTInhibikase Therapeutics, Inc.$6.02M1.45%2.71%Not reportedQ4 2025
MAZEMaze Therapeutics, Inc.$5.97M1.44%0.40%NewQ1 2026
ANTXAN2 Therapeutics, Inc.$5.58M1.34%4.62%NewQ1 2026
LXEOLexeo Therapeutics, Inc.$5.33M1.28%1.25%+430.6%Q4 2025
HLXCHelix Acquisition Corp. III$5.08M1.22%Not reportedNewQ1 2026
ALECAlector, Inc.$4.52M1.09%1.89%+87.9%Q4 2025
LONALeonaBio, Inc.$3.84M0.92%4.19%Not reportedQ4 2025
CRVSCorvus Pharmaceuticals, Inc.$3.39M0.81%0.28%NewQ1 2026
Q4 2025Reported Feb 13, 202627 positions
CDTXCidara Therapeutics, Inc.$51.3M16.95%0.74%NewQ4 2025
RLAYRelay Therapeutics, Inc.$25.2M8.34%1.72%NewQ4 2025
LBRXLB Pharmaceuticals Inc$22.4M7.40%3.97%NewQ4 2025
RLMDRelmada Therapeutics, Inc.$19.7M6.52%5.57%NewQ4 2025
PCVXVaxcyte, Inc.$18.5M6.10%0.31%NewQ4 2025
KNSAKiniksa Pharmaceuticals International, plc$17.9M5.93%Not reportedNewQ4 2025
EYPTEyePoint, Inc.$17.9M5.93%1.19%NewQ4 2025
SVRASavara Inc$14.5M4.80%1.18%NewQ4 2025
ERASErasca, Inc.$14.5M4.78%1.37%NewQ4 2025
DNTHDianthus Therapeutics, Inc.$12.3M4.05%0.69%NewQ4 2025
SRZNSurrozen, Inc.$9.76M3.23%4.42%NewQ4 2025
OCULOcular Therapeutix, Inc$9.52M3.14%0.36%NewQ4 2025
SABSSAB Biotherapeutics, Inc.$8.22M2.72%4.62%NewQ4 2025
IKTInhibikase Therapeutics, Inc.$7.34M2.43%2.72%NewQ4 2025
ELVNEnliven Therapeutics, Inc.$6.87M2.27%0.75%NewQ4 2025
NERVMinerva Neurosciences, Inc.$6.66M2.20%3.83%NewQ4 2025
ABVXAbivax S.A.$6.62M2.19%0.06%NewQ4 2025
HELPCybin Inc.$6.3M2.08%3.56%NewQ4 2025
KALVKalVista Pharmaceuticals, Inc.$6.27M2.07%0.76%NewQ4 2025
ENTAEnanta Pharmaceuticals Inc$6.15M2.03%1.34%NewQ4 2025
ANROAlto Neuroscience, Inc.$3.97M1.31%0.70%NewQ4 2025
LONALeonaBio, Inc.$2.98M0.98%4.22%NewQ4 2025
CNTACentessa Pharmaceuticals PLC$1.95M0.64%0.05%NewQ4 2025
ALECAlector, Inc.$1.74M0.58%1.01%NewQ4 2025
LXEOLexeo Therapeutics, Inc.$1.74M0.57%0.24%NewQ4 2025
IPSCCentury Therapeutics, Inc.$1.41M0.47%1.62%NewQ4 2025
STROSutro Biopharma, Inc.$875K0.29%0.88%NewQ4 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.